Key Market Indicators
Costa Rican antirheumatic medicine sales are expected to reach around $2.5 million in the next five years, down 1.1 percent annually on average. Since 2012, the Costa Rican market has declined by almost 5 percent each year. In 2021, Costa Rica ranked 26th, behind Iceland with $2.6 million. Germany, Spain and Canada were the next three biggest markets in the ranking.
